In short
Clinical trials are investigating SIPAVIBART for prevention of COVID-19. These studies look at safety and how well it may help stop symptomatic COVID-19 in adults at risk, including people who were SARS-CoV-2 negative at the start. The main trial is a Phase 3 study.
Key points
- SIPAVIBART is being studied in clinical trials for prevention of COVID-19. The main trial listed is a Phase 3 interventional study with 3,349 participants and a completed status. Researchers are looking at whether it can help prevent symptomatic COVID-19 caused by any SARS-CoV-2 variant and by matched variants. The trial also measures safety outcomes such as adverse events, serious adverse events, medically attended adverse events, and events of special interest. The study includes a main cohort and a sentinel safety cohort.
Trial overview
The clinical trial data for SIPAVIBART describes one main study, called SUPERNOVA, which was designed to look at prevention of COVID-19. It was an interventional study, which means researchers gave a study treatment and then measured the results.
The trial was in Phase 3, which is a later stage of testing in a larger group of people. The study status was completed.
Who was studied
The main study focused on people in a SARS-CoV-2-negative set, meaning they did not have evidence of current SARS-CoV-2 infection at the start of the trial. The source data does not provide more detailed eligibility rules, so the exact full entry criteria are not listed here.
The trial also included a sentinel safety cohort, which is a smaller group used to watch safety closely at the start of treatment.
What the trials measured
The main goal was to evaluate safety and compare how well SIPAVIBART worked in preventing symptomatic COVID-19. The study compared SIPAVIBART with EVUSHELD and/or placebo, depending on the cohort and study setup.
One key outcome was the occurrence of adverse events, including serious adverse events, medically attended adverse events, and adverse events of special interest. These were collected during the study and for about 90 days after each study treatment dose in the main cohort, and during the study in the sentinel safety cohort.
Another main outcome was the first confirmed symptomatic COVID-19 case, measured from the time of the first dose until the participant developed symptoms. Researchers also measured cases caused by matched variants, which the source defines as variants that do not contain the F456L mutation.
Study design and cohorts
The trial had a main cohort and a sentinel safety cohort. The main cohort was used to compare prevention of symptomatic COVID-19 and to assess safety in the larger study group.
The brief summary says the main cohort aimed to evaluate the safety of SIPAVIBART and EVUSHELD and/or placebo, and to compare SIPAVIBART with EVUSHELD and/or placebo for prevention of symptomatic COVID-19 caused by any SARS-CoV-2 variant. It also aimed to compare prevention of symptomatic COVID-19 caused by matched variants.
The sentinel safety cohort was used to evaluate safety with close monitoring. This kind of cohort helps researchers watch for safety issues early and carefully.
Trial status and size
The study enrolled 3,349 participants. That makes it a large Phase 3 trial, which is important for learning more about both safety and preventive effect in a broad study group.
The only trial provided in the source data is NCT05648110, so the article summary reflects this single study rather than a larger set of SIPAVIBART trials.